By Paige Minemyer
Optum has quietly acquired Refresh Mental Health from private equity firm Kelso & Company, Axios reported Thursday.
read more
By Fraiser Kansteiner
The FDA has pushed back its decision on Reblozyl, also known as luspatercept-aamt, by three months. The regulator now plans to issue a verdict on the drug for anemia in adults with non-transfusion dependent beta thalassemia by June 27.
read more
By Max Bayer
Early underwhelming data from Icosavax's COVID-19 vaccine has sent investors sprinting towards the exits, bringing into question whether the biotech's entire platform has a "fatal flaw."
read more
By Fraiser Kansteiner
As Congress gridlocks over new funding for COVID-19 therapies and vaccines, mRNA bigwig Moderna is setting its sights on the endemic market for its wildly successful shot.
read more
By Andrea Park
It’s only been a few months since Roche started inviting artificial intelligence developers like PathAI into its cancer-focused digital pathology platform, but it’s already going all-in on the technological team-up.
read more
By Dave Muoio
The legislation was brought to the Senate just days after the Biden administration warned of potential cyberattacks from Russia.
read more
By Nick Paul Taylor
AN2 Therapeutics has found public investors willing to bet on biotech, enabling it to upsize its IPO and reel in $69 million for a pivotal trial of an antibiotic it picked up from Pfizer’s Anacor Pharmaceuticals.
read more
By Conor Hale
After receiving an FDA approval last month in bladder and bowel incontinence for its neuromodulation device implanted in the lower back, Medtronic isn’t resting on its laurels. Now, it's testing a similar device implanted near the ankle instead.
read more
By Fraiser Kansteiner
Jazz will invest more than $100 million into a new, 60,000-square-foot production facility in the U.K., where it also plans to hire 100 new staffers. The plant is expected to open in 2024, and it will specifically support manufacture of Jazz and GW’s two approved cannabis-based medicines.
read more
By Annalee Armstrong
89bio has gained a little more confidence in its non-alcoholic steatohepatitis therapy after new data showed the treatment increased levels of a key hormone linked to anti-inflammatory and anti-fibrotic activity in the liver.
read more
By Robert King
The American Hospital Association made its latest foray into venture capital, becoming the newest investor in the women's health startup fund SteelSky Ventures.
read more
By Andrea Park
Buoyed by tens of millions in new revenue and a successful IPO that brought in proceeds of more than a quarter-billion dollars, Sight Sciences is scoping out new avenues to deliver ophthalmic treatments.
read more
By Paige Minemyer
This year, Fierce Healthcare's #FierceMadness is back, and we want you to help us identify the industry's most influential person.
read more
